The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Final results from the phase Ib/II study (PX-171-006) of carfilzomib, lenalidomide, and low-dose dexamethasone (CRd) in patients with relapsed or progressive multiple myeloma.
Michael Wang
Honoraria - Celgene
Research Funding - Celgene; Millennium; Novartis; Onyx
Thomas Martin
Consultant or Advisory Role - Onyx
Honoraria - Celgene
Research Funding - Onyx
William Bensinger
Consultant or Advisory Role - Onyx
Research Funding - Onyx
Melissa Alsina
Consultant or Advisory Role - Millennium; Novartis
Research Funding - Allergan; Millennium
David Samuel DiCapua Siegel
Consultant or Advisory Role - Celgene; Millennium; Onyx
Honoraria - Celgene; Millennium
Edward Kavalerchik
Employment or Leadership Position - Onyx
Ruben Niesvizky
Honoraria - Onyx